FluoroPharma's cardiac PET tracer shows promise

02/10/2014 | MolecularImaging.net

FluoroPharma Medical presented preliminary results from a Phase II clinical trial of its F-18 FCPHA cardiac PET agent last week. "F-18 FCPHA was well-tolerated and administered safely in study subjects at [the University of Louvain], part of a multicenter study in Belgium. F-18 FCPHA demonstrated rapid blood clearance with excellent image quality and image time was optimal, as early as three minutes post- injection," said researcher Dr. Fabian Demeure.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD